PharmaCyte Biotech, Inc.

NasdaqCM:PMCB Stock Report

Market Cap: US$7.7m

PharmaCyte Biotech Management

Management criteria checks 4/4

PharmaCyte Biotech's CEO is Josh Silverman, appointed in Oct 2022, has a tenure of 3.75 years. total yearly compensation is $520.26K, comprised of 72.1% salary and 27.9% bonuses, including company stock and options. directly owns 3.88% of the company’s shares, worth $297.62K. The average tenure of the management team and the board of directors is 7.6 years and 4.5 years respectively.

Key information

Josh Silverman

Chief executive officer

US$520.3k

Total compensation

CEO salary percentage72.08%
CEO tenure3.8yrs
CEO ownership3.9%
Management average tenure7.6yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Analysis Article • Mar 22

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 07

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech (NASDAQ:PMCB) on Friday announced that its CEO Kenneth Waggoner had stepped down and said its board had authorized a business review committee to evaluate strategic opportunities for the company. Las Vegas, Nev. based PMCB is a biotech that is evaluating its live-cell encapsulation technology called Cell-in-a-Box for the potential development of therapies for cancer, diabetes and ascites, which is a condition in which fluid collects in the spaces within the abdomen. PMCB said its live-cell encapsulation technology involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. The company said it had appointed Joshua Silverman as interim CEO. The company also said it was assessing the concerns expressed by the U.S. FDA relating to the clinical hold placed on its investigational new drug application for the Cell-in-a-Box technology. PMCB stock +1.2% to $2.51 in early trading.
Seeking Alpha • Aug 15

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

PharmaCyte Biotech (NASDAQ:PMCB) said on Monday that it had signed a cooperation agreement with Iroquois Master Fund and its affiliates to includes two of Iroquois’ director designees to its Board of Directors. (PMCB) rose ~4% before the bell. Iroquois’ director designees, Jonathan Schechter and Joshua Silverman, will join PharmaCyte’s reconstituted Board as independent directors, the company said. "We are nearing the end of our process to fulfill the FDA’s requests to enable the clinical hold to be lifted. To date, approximately 90% of the FDA’s requests have been completed or are in process with one major pig study remaining to be completed," said PharmaCyte’s Chief Executive Officer, Kenneth Waggoner. Iroquois has agreed to certain customary standstill provisions and will support the Board’s full slate of directors at the 2022 Annual Meeting.
Seeking Alpha • Jan 07

Is This A Good Time To Invest In PharmaCyte?

PharmaCyte has developed a cell encapsulation technique that allows foreign cells to be injected into the body without triggering an immune response. The company is using their encapsulation technique as a basis for developing treatments for diabetes and cancer. Currently, the company has no income stream. Financing is entirely from the sale of corporate stock.
Seeking Alpha • Aug 21

PharmaCyte Biotech: Buy The 'Dump'

I recommend that you nibble a few shares of PharmaCyte Biotech if interested in a “trade” or a very high-risk long-term buy-and-hold. Historically, the company (or its investors) has proved to be quite expert in self-promotion. Your entry price per share should be at or below $4.25. The direct offering is for 14 million shares plus up to 7 million shares, through warrants, for minimum proceeds of $70 million. Gross proceeds from NASDAQ offering for $15 million plus the $70 million direct offering will be used for Phase 2b clinical trials.

CEO Compensation Analysis

How has Josh Silverman's remuneration changed compared to PharmaCyte Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Jan 31 2026n/an/a

-US$7m

Oct 31 2025n/an/a

-US$8m

Jul 31 2025n/an/a

US$44k

Apr 30 2025US$520kUS$375k

US$23m

Jan 31 2025n/an/a

US$10m

Oct 31 2024n/an/a

US$7m

Jul 31 2024n/an/a

US$7m

Apr 30 2024US$840kUS$375k

-US$17m

Jan 31 2024n/an/a

-US$15m

Oct 31 2023n/an/a

-US$10m

Jul 31 2023n/an/a

-US$10m

Apr 30 2023US$198kUS$188k

-US$4m

Compensation vs Market: Josh's total compensation ($USD520.26K) is about average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.

CEO

Josh Silverman (56 yo)

3.8yrs
Tenure
US$520,257
Compensation

Mr. Joshua N. Silverman, also known as Josh, is Executive Chairman of the Board of Petros Pharmaceuticals, Inc. from August 2025. Mr. Silverman was Independent Chairman of the Board of Petros Pharmaceutica...

Leadership Team

NamePositionTenureCompensationOwnership
Joshua Silverman
CEO. President & Executive Chairman3.8yrsUS$520.26k3.88%
$ 297.6k
Carlos Trujillo
Chief Financial Officer9.3yrsUS$482.02k0.097%
$ 7.4k
Jose Iglesias
Consulting Chief Medical Officer5.9yrsno datano data
Hans-Peter Hammes
Member of Medical & Scientific Advisory Board and Consultant10.7yrsno datano data
7.6yrs
Average Tenure
68yo
Average Age

Experienced Management: PMCB's management team is seasoned and experienced (7.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joshua Silverman
CEO. President & Executive Chairman3.9yrsUS$520.26k3.88%
$ 297.6k
Hans-Peter Hammes
Member of Medical & Scientific Advisory Board and Consultant10.7yrsno datano data
Robert Weinstein
Independent Director3.7yrsUS$130.00k0.38%
$ 29.5k
Brian Salmons
Member of Medical & Scientific Advisory Board10.2yrsno datano data
Matthias Löhr
Chairman of Medical & Scientific Advisory Board4.5yrsUS$16.76kno data
Michael Abecassis
Independent Director9yrsUS$162.00k0.21%
$ 15.9k
Wayne Walker
Independent Director3.6yrsUS$130.00k0.19%
$ 14.7k
Mark Rabe
Member of Medical & Scientific Advisory Boardno datano datano data
Jonathan Schechter
Independent Director3.9yrsUS$130.00k1.79%
$ 137.6k
David Judd
Member of Medical & Scientific Advisory Board7yrsno datano data
4.5yrs
Average Tenure
66yo
Average Age

Experienced Board: PMCB's board of directors are considered experienced (4.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/05 07:11
End of Day Share Price 2026/07/02 00:00
Earnings2026/01/31
Annual Earnings2025/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaCyte Biotech, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WhiteH.C. Wainwright & Co.